{
    "guideline": {
        "id": "PA166262281",
        "name": "Annotation of CPIC Guideline for pravastatin and SLCO1B1",
        "source": "CPIC",
        "version": 4,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262281",
        "relatedChemicals": [
            {
                "id": "PA451089",
                "name": "pravastatin",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA134865839",
                "name": "solute carrier organic anion transporter family member 1B1",
                "symbol": "SLCO1B1"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166298457",
            "name": "Recommendation PA166298457",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061059,
                "html": "<p>Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses \u226440 mg."
            ],
            "lookupKey": {
                "SLCO1B1": "Possible Decreased Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298458",
            "name": "Recommendation PA166298458",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061060,
                "html": "<p>Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses &gt;40mg per day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses \u226440 mg."
            ],
            "lookupKey": {
                "SLCO1B1": "Decreased Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298459",
            "name": "Recommendation PA166298459",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061061,
                "html": "<p>Prescribe \u226440mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (&gt;40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses &gt;40mg.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses \u226440 mg."
            ],
            "lookupKey": {
                "SLCO1B1": "Poor Function"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298455",
            "name": "Recommendation PA166298455",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061057,
                "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
            },
            "implications": [
                "SLCO1B1: Typical myopathy risk and statin exposure"
            ],
            "lookupKey": {
                "SLCO1B1": "Increased Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298456",
            "name": "Recommendation PA166298456",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061058,
                "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
            },
            "implications": [
                "SLCO1B1: Typical myopathy risk and statin exposure"
            ],
            "lookupKey": {
                "SLCO1B1": "Normal Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298460",
            "name": "Recommendation PA166298460",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451089",
                    "name": "pravastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061062,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "SLCO1B1: n/a"
            ],
            "lookupKey": {
                "SLCO1B1": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "35152405",
            "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
            "authors": [
                "Cooper-DeHoff Rhonda M",
                "Niemi Mikko",
                "Ramsey Laura B",
                "Luzum Jasmine A",
                "Tarkiainen E Katriina",
                "Straka Robert J",
                "Gong Li",
                "Tuteja Sony",
                "Wilke Russell A",
                "Wadelius Mia",
                "Larson Eric A",
                "Roden Dan M",
                "Klein Teri E",
                "Yee Sook Wah",
                "Krauss Ronald M",
                "Turner Richard M",
                "Palaniappan Latha",
                "Gaedigk Andrea",
                "Giacomini Kathleen M",
                "Caudle Kelly E",
                "Voora Deepak"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2022
        }
    ],
    "version": "2024-03-25-16-13"
}